Executive Summary

National Cancer Institute Gastrointestinal Steering Committee

Neuroendocrine Tumor Clinical Trials Planning Meeting:
Treatment in the Era of Peptide Receptor Radionuclide Therapy

March 8-9, 2021

Meeting Co-Chairs: Thomas Hope, M.D., Pamela Kunz, M.D., and Simron Singh M.D., M.P.H., with Wolf Lindwasser, Ph.D. and Elise C. Kohn, M.D.

Meeting Description

The National Cancer Institute (NCI) Gastrointestinal Steering Committee (GISC) convened the Clinical Trials Planning Meeting for Neuroendocrine Tumors: Treatment in the Era of Peptide Receptor Radionuclide Therapy (PRRT) on March 8-9, 2021. Meeting attendees included GISC members, members of the GISC Neuroendocrine Tumor Task Force (NET TF), physicians, new investigators, researchers, patient advocates, NCI staff, and invited representatives from industry. The purpose of the meeting was to identify clinical trial strategies to help define the treatment of patients with neuroendocrine tumors (NETs) in the era of PRRT.

Background

Important progress has been made over the last decade in the classification, imaging, and treatment of NETs, with several new agents approved for use. Refinements of the pathologic classification reflect recognition of the value of Ki67/mitotic rate (WHO 2010)¹ and the presence of a well differentiated G3 entity (WHO 2017)². In addition, our understanding of the molecular underpinnings of well-differentiated pancreatic NETs (panNETs) has advanced considerably³⁵. Telotristat was approved for symptom control in patients with refractory carcinoid syndrome.⁶ The antitumor activity of somatostatin analogs, mTOR, and VEGFR inhibition has been established, leading to the approval of lanreotide (for gastroenteropancreatic NETs [GEP-NET])⁷, everolimus (gastrointestinal, lung, and panNETs)⁸⁹ and sunitinib (panNETs)¹⁰. Capecitabine and temozolomide has become the de facto standard of care chemotherapy in recurrent panNET based on retrospective data¹¹ and the results of E2211¹². Somatostatin receptor (SSTR) PET imaging (⁶⁸Ga-DOTATATE, ⁶⁸Ga-DOTATOC and ⁶⁴Cu-DOTATATE) has emerged as a common imaging modality both for staging and selecting patients for PRRT, replacing SSTR-based scintigraphy¹³. Perhaps the biggest development over the last decade has been the approval of ¹⁷⁷Lu-DOTATATE PRRT therapy for treatment of GEP-NETs¹⁴.

¹ NCI GISC Neuroendocrine Tumor CTPM – Executive Summary
While the treatment options available for patients with well differentiated NETs have greatly expanded, the rapidly changing landscape has left us with a number of unanswered questions about how best to optimize, sequence, and individualize therapy. In particular, the approval by FDA of $^{177}$Lu-DOTATATE in SSTR-positive GEP-NETs has attracted great enthusiasm (HR 0.21, median PFS not reached vs. 8 months compared to high dose octreotide LAR, $p<0.001$)\textsuperscript{14}. Treatment is associated with the longest progression-free survival (PFS) reported in somatostatin analog-refractory midgut NETs, although the radiographic response rate is low (18%). Limited retrospective data suggest $^{177}$Lu-DOTATATE is associated with higher response rates in panNETs, but prospective studies are needed\textsuperscript{15}. Furthermore, $^{177}$Lu-DOTATATE appears to be associated with a small but significant risk of myelodysplastic syndrome or acute myeloid leukemia (2.7% at 2 years\textsuperscript{16}), a clinically-relevant toxicity in patients with a median overall survival (OS) measured in years (6 years for stage IV panNET, 10+ years for small bowel NETs)\textsuperscript{17}.

**Consensus & Recommendations**

Neuroendocrine neoplasms are a heterogeneous set of diseases for which either separate trials should be conducted by primary site for bronchial, midgut, panNETs; alternatively, stratification by primary site should be considered if separate trials are not feasible. Additionally, stratification for grade and differentiation should be built into study designs. Consideration should also be made for both the number and types of prior therapies. Investigators should attempt to harmonize the definition of SSTR positivity and account for intratumoral heterogeneity in expression in designing SSTR-based therapy trials.

The recent advances in the field also led to the recognition that questions remain around optimal sequencing of PRRT relative to other therapeutic options, the role of retreatment with PRRT, and whether or not PRRT can be further optimized, refined or decrease toxicity by using PRRT combination therapy and/or an individualized approach to dosing. There was consensus that answering these questions via clinical trials must be considered in the context of the life cycle of the disease and by grade of disease and extent and location of disease (see figure 1).

Detailed discussions on trial opportunities were initiated two years before the CTPM, which was delayed a year due to the COVID-19 pandemic. Topics for which published and ongoing studies were evaluated included:

a) mechanisms to enhance efficacy, role and response to PRRT;

b) timing, sequencing and dosimetry;

c) the role of subsequent therapy in both PRRT resistant and PRRT sensitive populations; and,

d) tenets/principles of care and trial design in the new era of discriminants for types of NET and treatment opportunities.

**Note:** Immediately following the March 2021 CTPM, the concept, A022001, a Phase II randomized, prospective trial of Lu-177 dotatate PRRT versus capecitabine and temozolomide in well-differentiated pancreatic neuroendocrine tumors, was approved by the GISC. This information of approval was NOT available at the CTPM and discussions were exclusive of this concept.
This study will be open to all well-differentiated panNET patients, all grades, with eligibility to be modified to remove overlap with CABINET (A021602) by requiring a change to enroll only symptomatic patients, or those with large tumor burdens (to be defined). As such, accrual to this new concept/protocol is likely to have an impact on the advancement of new potential studies in the panNET clinical space, with the exception of phase 1 and signal-finding studies.

**Figure 1.** National Clinical Trials Network (NCTN) trials for neuroendocrine neoplasms (NENs). Abbreviations used in the figure: NEC (neuroendocrine carcinoma), Para (paraganglioma), Pheo (pheochromocytoma), CapTem (capecitabine and temozolomide), Obs (observation), Atezo (atezolizumab), fb (followed by), EP (etoposide and platinum [carboplatin or cisplatin]), PBO (placebo).

### NCTN NEN Trials

<table>
<thead>
<tr>
<th>Adjuvant</th>
<th>Metastatic</th>
</tr>
</thead>
<tbody>
<tr>
<td>PanNET</td>
<td>GEPNET</td>
</tr>
<tr>
<td>GI NET</td>
<td></td>
</tr>
<tr>
<td>Bronchial NET</td>
<td></td>
</tr>
<tr>
<td>NEC</td>
<td></td>
</tr>
<tr>
<td>Para/Pheo</td>
<td></td>
</tr>
</tbody>
</table>

- **Adjuvant:**
  - Adjuvant CapTem vs. Obs (S2104)
  - Cabozantinib vs. PBO in pNET and carcinoid (GI + Lung) (CABINET, A021602)

- **Metastatic:**
  - $^{177}$Lu-Dotatate vs. CapTem (A022001)
  - $^{177}$Lu-Dotatate vs. Everolimus (A021901)
  - EP+Atezo fb Atezo vs. EP+Atezo fb Obs vs. EP fb Obs small cell (S2012)
  - Tem vs. Tem + Olaparib (A021804)

*Newly approved studies*

**Proposed Concepts**

The following concepts were developed by working groups prior to the CTPM and further refined during the meeting (see figure 2). They were then prioritized by which were deemed feasible to undertake concept development immediately (high priority), consideration for an intermediate timeline for development due to requirement for further data or data maturation, and a final category where is was concluded there was a need for preclinical data, clinical data and/or other advances to be made.
Immediate term:

- **NET RETREAT (SWOG/CCTG):** Randomized phase 2 study of repeat $^{177}$Lu-DOTATATE vs. everolimus in previously PRRT-treated midgut NET
  - Metastatic, WD, G1-2, midgut, at least 12 months durable response after initial PRRT
  - Will provide key prospective clinical data regarding retreatment benefit, cumulative toxicity and myelotoxicity risks
- **Modified PRRT (mPRRT):** “Standard” PRRT (4 cycles) vs. mPRRT (2-8 cycles with goal of 80-130 Gy total dose in lesions > 3cm)
  - Overlaps patient population eligible for A022001
  - Metastatic, WD, G1-2, panNET, RECIST progression in last 12 months, SSTR+, 2 lesions ≥ 3cm, no prior PRRT
  - Could be done front line or incorporated into RETREAT
Medium term (awaiting near-term data):

- Immunotherapy Combination Trial: \(^{177}\text{Lu-DOTATATE} \pm \text{PD-1 inhibitor}\)
  - Metastatic WD, aggressive G2/3, GEP NET, SSTR+, any line
  - Awaiting preclinical or other clinical data to support development
  - Phase 1 lead-in/randomized phase 2 design
  - Will form working group to support development
  - Risk of overlap patient population eligible for A022001

- DNA Damage Repair Combination Trial: Randomized “pick the winner design” Phase 2/3 study of \(^{177}\text{Lu-DOTATATE}\) with DNA damage repair (DDR)
  - Patients randomized 1:1:1:1 to triapine, olaparib, or peposertib + \(^{177}\text{Lu-DOTATATE}\), or \(^{177}\text{Lu-DOTATATE}\) alone
  - Metastatic, WD G2/3, Ki67 between 5-55%, GEP-NETs, SSTR+, any line, progressive disease within 12 months of enrollment.
  - Awaiting data from ETCTN 10388, 10450, and CCR/NCI studies
  - Will form working group to support development

Needs more development/long term:

- SABR trial: PRRT +/- stereotactic ablative radiation (SABR) for heterogeneous metastatic WD high-risk limited metastases NETs
  - Metastatic, WD G2/3, Ki67 between 10-55%, GEP-NETs, SSTR+, any line
  - Will form working group to support development

- Debulking trial: \(^{177}\text{Lu-DOTATATE}\) vs. LDT followed by \(^{177}\text{Lu-DOTATATE}\)
  - Metastatic, WD G1-3, SBNETs, SSTR+
  - Testing role and timing of LDT and PRRT
  - Need to identify optimal patient population and design

- ENHANCE PRRT: Escalating Neuroendocrine Therapy for Incomplete Responders to PRRT: Randomized phase 2 study of \(^{177}\text{Lu-DOTATATE} + \text{Cape vs. }^{177}\text{Lu-DOTATATE} + \text{Atezo}\)
  - Metastatic, WD G1-3, GEPNETs, SSTR+, PD within 12 months after completion of prior PRRT
  - Needs further work on design

- Window of opportunity trial: \(^{177}\text{Lu-DOTATATE} + \text{HDAC inhibitor}\)
  - Awaiting preclinical data

This Executive Summary presents the consensus arising from the CTPM. These recommendations are not meant to address all clinical contexts, but rather represent priorities for publicly funded clinical research.
Anticipated Actions

- Multidisciplinary, diverse, and inclusive working groups will be formed to foster the development of several proposed trials.
- We encourage involvement of multiple NCTN groups and partnerships between junior investigators (i.e., no prior NCTN trial leadership) and senior mentors.
- A paper will be prepared for documentation of meeting outcomes and recommendations.

References


Monday, March 8 – Day 1

10:00 – 10:15 am ET  Welcome and Introduction (Wolf Lindwasser, Elise Kohn, Tom Hope, Pam Kunz, Simron Singh)
Outline of the process, goals and deliverables

10:15 – 10:30  Disease life cycle considerations and Trial development (Pam Kunz, Simron Singh)

Session 1: Enhancing Efficacy and Increasing Response of PRRT (Moderator: Pam Kunz)

10:30 – 10:45  Improving the affinity and modulating SSTRs – Brian Untch

10:45 – 11:00  Enhancing response in immunotherapy and radiation – Sandra Demaria

11:00 – 11:15  Combination Therapy – Aman Chauhan

11:15 – 11:30  Role of Alpha emitters – Robert Hobbs

11:30 – 11:45  Discussion

11:45 – 12:30 pm  Break

Session 2: Timing, Sequencing and Dosimetry (Moderator: Tom Hope)

12:30 – 12:45  Practical experience of dosimetry trials in PRRT – Rebecca Wong

12:45 – 1:00  Timing, Freq and role of Repeat PRRT – Lisa Bodei

1:00 – 1:15  Minimizing and preventing Toxicity in PRRT - Andrew Kennedy

1:15 – 1:30  Cytoreductive therapy and sequencing of PRRT – Emily Bergsland

1:30 – 1:45  Discussion
**Session 3: Industry Presentations** (Moderator: Simron Singh)

1:45 – 1:50  ITM – Mona Wahba

1:50 – 1:55  Exelixis – Stephen Salatan

1:55 – 2:00  Novartis – Germo Gericke, Antonio Nakasoto

2:00 – 2:05  Ipsen – Sandy McEwan, Tom Beveridge

2:05 – 2:40  Discussion

2:40  Recuse Industry Partners from Open Session of Meeting

2:40 – 2:50  Break

**Session 4: Concept Presentations and Discussion** (Moderator: Tom Hope)

2:50 – 3:05  Group 1 – Simron Singh, Jennifer Chan

3:05 – 3:20  Group 2 – Pam Kunz, Heloisa Soares

3:20 – 3:35  Group 3 – Tom Hope, David Bushnell

3:35 – 4:30  Discussion

**Breakout Session 1: Assessing the Proposed Concepts**

4:30 – 5:30  Breakout Group 1 (Co-leaders: Singh, Chan)

Breakout Group 2 (Co-leaders: Kunz, Soares)

Breakout Group 3 (Co leaders: Hope, Bushnell)

5:30  End of Day 1

5:30 – 6:30  CTPM Co-Chairs Meeting (Closed)
Tuesday, March 9 – Day 2

10:00 – 10:10 am ET  Welcome to Day 2, Day 1 overview – CTPM co-chairs

Session 5: Clinical Trial Design (Moderator: Simron Singh)

10:10 – 10:25  Appropriate endpoints in PRRT trials and biomarker assessment/correlatives (Primary and Secondary) – Marianne Pavel

10:25 – 10:40  Using Phase 2 trial designs to inform Phase 3/ standardizing eligibility criteria – Daniel Halperin

10:40 – 10:55  Innovative Trial designs for potential PRRT trials (e.g., adaptive trial design) – Fang-Shou Ou

10:55 – 11:10  Assessing Imaging and endpoints in PRRT trials – Frank Lin

11:10 – 11:25  Discussion

Session 6: Principles of Clinical Trial Design (Moderators: Simron Singh/Jen Chan)

11:25 – 12:20 pm  Discussion

12:20 – 1:00  Break

1:00 – 1:10  Navigating Next Steps – Elise Kohn

Session 7: Finalizing the Concepts (Moderator: Tom Hope)

1:10 – 2:20  Discussion

2:10 – 2:30  Wrap up and Adjourn – Co-chairs

2:30 – 3:30  Executive Planning Committee meeting (Closed)
<table>
<thead>
<tr>
<th>Name</th>
<th>Title</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Emily Bergsland, M.D.</td>
<td>Professor of Clinical Medicine</td>
<td>UCSF</td>
</tr>
<tr>
<td>Tom Beveridge, B.Sc., Ph.D.</td>
<td>Senior Director, Medical Affairs - Oncology</td>
<td>Ipsen Biopharmac</td>
</tr>
<tr>
<td>Lisa Bodei, M.D., Ph.D.</td>
<td>Attending Physician, Director, Targeted Radionuclide Therapy</td>
<td>Memorial Sloan Kettering Cancer Center</td>
</tr>
<tr>
<td>Anita Borek, M.B.A., B.S.</td>
<td>Senior Medical Scientific Director</td>
<td>Genentech</td>
</tr>
<tr>
<td>Michelle Brockman, M.B.A.</td>
<td>Principal Medical Science Director Scientific Collabs</td>
<td>Genentech US Medical Affairs</td>
</tr>
<tr>
<td>David Bushnell, M.D.</td>
<td>Professor</td>
<td>University of Iowa</td>
</tr>
<tr>
<td>Jacek Capala, Ph.D.</td>
<td>Program Director</td>
<td>National Cancer Institute</td>
</tr>
<tr>
<td>Jennifer Chan, M.D., M.P.H.</td>
<td>Assistant Professor of Medicine</td>
<td>Harvard Medical School</td>
</tr>
<tr>
<td>Beth Chasen, M.D.</td>
<td>Professor</td>
<td>MD Anderson Cancer Center</td>
</tr>
<tr>
<td>Aman Chauhan, M.D.</td>
<td>Assistant Professor of Medicine</td>
<td>University of Kentucky</td>
</tr>
<tr>
<td>Satya (Nanu) Das, M.D., M.Sci.</td>
<td>Assistant Professor of Medicine</td>
<td>Vanderbilt University Medical Center</td>
</tr>
<tr>
<td>N. Arvind Dasari, M.D., M.S.</td>
<td>Associate Professor</td>
<td>MD Anderson Cancer Center</td>
</tr>
<tr>
<td>Cynthia Davies-Venn, Ph.D.</td>
<td>Information Specialist</td>
<td>Emmes Corp</td>
</tr>
<tr>
<td>Jaydira Del Rivero, M.D.</td>
<td>Assistant Research Physician</td>
<td>National Cancer Institute</td>
</tr>
<tr>
<td>Sandra Demaria, M.D.</td>
<td>Professor of Radiation Oncology and Pathology</td>
<td>Weill Cornell Medical College</td>
</tr>
<tr>
<td>Martha Donoghue, M.D.</td>
<td>Deputy Division Director</td>
<td>Food and Drug Administration</td>
</tr>
<tr>
<td>Jennifer Eads, M.D.</td>
<td>Associate Professor</td>
<td>University of Pennsylvania</td>
</tr>
<tr>
<td>Ghassan El-Haddad, M.D.</td>
<td>Associate Professor Interventional Radiology</td>
<td>H Lee Moffitt Cancer Center and Research Institute</td>
</tr>
<tr>
<td>Lauren Fishbein, M.D., Ph.D.</td>
<td>Associate Professor</td>
<td>University of Colorado</td>
</tr>
<tr>
<td>Germo Gericke, Ph.D.</td>
<td>Chief Medical Officer</td>
<td>Advanced Accelerator Applications intl</td>
</tr>
<tr>
<td>Karyn Goodman, M.D.</td>
<td>Professor</td>
<td>Icahn School of Medicine at Mount Sinai</td>
</tr>
<tr>
<td>Axel Grothey, M.D.</td>
<td>Medical Oncologist, Director GI Cancer Research</td>
<td>The West Cancer Center &amp; Research Institute</td>
</tr>
</tbody>
</table>
Daniel Halperin, M.D.
Assistant Professor
MD Anderson Cancer Center

Andrew Hendifar, M.D.
Medical Director
Cedars-Sinai Medical Center

Rodney Hicks, M.B.B.S., M.D.
Director, Molecular Imaging and Therapeutic Nuclear Medicine
The Peter MacCallum Cancer Centre

Robert Hobbs, Ph.D., D.A.B.R.
Associate Professor
Johns Hopkins University

Timothy Hobday, M.D.
Consultant
Mayo Clinic

Thomas Hope, M.D.
Associate Professor
UCSF

Renuka Iyer, M.D.
Chief, DOM GI Center
Roswell Park Comprehensive Cancer Center

Deborah Jaffe, Ph.D.
Associate Director for Scientific Steering Committees
National Cancer Institute

Andrew Kennedy, M.D., F.A.C.R.O.
Physician-in-Chief Radiation Oncology
Sarah Cannon

Elise Kohn, M.D.
Senior Investigator and Head, Gynecologic Cancer Therapeutics
National Cancer Institute

Matthew Kulke, M.D.
Professor
Boston University School of Medicine

Pamela Kunz, M.D.
Associate Professor
Yale School of Medicine and Yale Cancer Center

Mark Lewis, M.D.
Director, Gastrointestinal Oncology
Intermountain Healthcare

Frank Lin, M.D.
Investigator
National Cancer Institute

Wolf Lindwasser, Ph.D.
Program Director
National Cancer Institute

Josh Mailman, M.B.A.
President
NorCal CarciNET Community

Sandy McEwan, MSc, M.D., F.R.C.P.C.
Vice President Radiopharmaceuticals
Ipsen Biopharma

Sten Myrehaug, M.D.
Radiation Oncologist
Odette Cancer Centre, University of Toronto

Antonio Nakasato, M.D.
Medical Director
Novartis Pharmaceuticals Corporation

Steve Nothwehr, Ph.D.
Program Director
National Cancer Institute

Fang-Shu Ou, Ph.D.
Assistant Professor
Mayo Clinic

Sukhmani Padda, M.D.
Assistant Professor of Medicine
Stanford University

Marianne Pavel, Prof. Dr.
Full Professor of Medicine and Endocrinology
University of Erlangen, Erlangen, Germany
Anthony Pilowa, B.S.
Director, Medical Affairs Operations
Exelixis, Inc

Nitya Raj, M.D.
Assistant Attending Physician
Memorial Sloan Kettering Cancer Center

Brian Ramnaraign, M.D.
Assistant Professor
University of Florida

Diane Reidy-Lagunes, M.S., M.D
Associate Deputy Physician-In-Chief
Memorial Sloan Kettering Cancer Center

Larry Rubinstein, Ph.D.
Statistician
National Cancer Institute

Stephen Saletan, M.D.
Medical Director
Exelixis

Manisha Shah, M.D.
Professor of Medicine
Ohio State University

Simron Singh, M.D., M.P.H.
Assistant Professor
University of Toronto

Heloisa Soares, M.D.
Assistant Professor
Huntsman Cancer Institute

Jonathan Strosberg, M.D.
Professor
Moffitt Cancer Center

Michael Soulen, M.D.
Professor
University of Pennsylvania

Brian Untch, M.D.
Assistant Attending
Memorial Sloan Kettering Cancer Center

Mona Wahba, M.D., M.S.M.
Deputy Chief Medical Officer
ITM

Rebecca Wong, M.B.Ch.B., M.Sc., F.R.C.P.
Radiation Oncologist
Princess Margaret Cancer Center

James Yao, M.D.
Professor
MD Anderson Cancer Center
NCI Neuroendocrine Tumor CTPM: Treatment in the Era of PRRT
Executive Planning Committee

Co-Chairs
Thomas Hope, M.D.
Pamela Kunz, M.D.
Simron Singh, M.D., M.P.H.

Members
Emily Bergsland, M.D.
David Bushnell, M.D.
Jennifer Chan, M.D., M.P.H.
N. Arvind Dasari, M.D., M.S.
Mark Lewis, M.D. (Patient Advocate)
Heloisa Soares, M.D.

GISC Co-Chairs
Karyn Goodman, M.D.
Axel Grothey, M.D.

NCI
Cynthia Davies-Venn, Ph.D. (Emmes)
Elise Kohn, M.D.
Wolf Lindwasser, Ph.D.